COVID-19 in lung-transplanted and cystic fibrosis patients: Be carefulÉric Farfour, Marc Vasse, Félix Ackermann et al.|Journal of Cystic Fibrosis|2020Cited by 17
The ID NOW COVID-19, a high-speed high-performance assayÉric Farfour, C Amiel, Marianne Asso‐Bonnet et al.|European Journal of Clinical Microbiology & Infectious Diseases|2021Cited by 16
<i>In Vitro</i> Susceptibility of Nonfermenting Gram-Negative Rods To Meropenem–Vaborbactam and DelafloxacinÉric Farfour, Marc Vasse, Louise Ruffier d’Epenoux et al.|Future Microbiology|2023Cited by 3
Tolérance de la prophylaxie anti CMV par Valganciclovir pendant 1 an chez les patients transplantés pulmonaire D+/R− étude rétrospective monocentriqueChristopher D. Roy, Antoine Roux, Sylvie Colin de Verdière et al.|Revue des Maladies Respiratoires Actualités|2021Cited by 0
Tolerance of Anti-CMV Prophylaxis with Valganciclovir One-Year Treatment in D+/R- Lung Transplant Patients. A Single-Center Retrospective StudyChristopher D. Roy, Antoine Roux, François Parquin et al.|The Journal of Heart and Lung Transplantation|2021Cited by 0